BM8 Stock Price, Chart, Stats & News

BioMarin Pharmaceutical Inc. is dedicated to discovering, developing, and marketing treatments for individuals suffering from serious and life-threatening rare diseases and medical conditions. Its current product portfolio features several key therapies: Vimizim, an enzyme replacement addressing mucopolysaccharidosis (MPS) IV type A; Naglazyme, a recombinant N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary oral formulation of 6R-BH4 used in the management of phenylketonuria (PKU). Other commercial offerings include Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to reduce blood phenylalanine concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for treating ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a daily injectable analog of c-type natriuretic peptide for achondroplasia; and Aldurazyme, a purified protein designed to replicate the human enzyme alpha-L-iduronidase.